About us

Investing in companies addressing high unmetmedical needs

We are a leading European venture capital firm. Our international team is driven by science, with the ambition to transform capital into medical breakthroughs.

We foster a positive impact on patients and society by funding the development of transformative treatments

Our philosophy

At Ysios Capital, the management team and strength
of science of each venture are key to our investment thesis.

We invest in companies bringing life-changing treatments to patients, with a focus on indications with high unmet need.

Our impact

 

14

medical products brought from
lab to market

>40

medical products at clinical
stage for serious diseases

>100

collaborations with leading
research institutions

>€1,000M

invested in
therapeutic R&D

Our focus

We invest globally in biotech ventures, focusing exclusively on innovative therapeutic drugs.

We seek exceptional teams with pioneering science and the drive to change patients' lives.

Our footprint

Ysios Capital was founded in 2008 and has offices in San Sebastian and Barcelona. We are the largest life sciences venture capital firm in Spain, with our investment successes providing a significant boost to the country’s biotech sector.

Since our inception, we have grown rapidly to become a leading global investment firm.

Our commitment

Ysios Capital is committed to responsible investment. We strive to integrate ESG principles and best practices across all our activities, as well as those of our portfolio companies and investors.

Sustainable development goals

Our funds provide venture capital to carefully selected private biotech companies developing novel therapeutics to address areas of critical unmet need

We manage over €400M ($500M ) in assets
across three global funds

Ysios BioFund III

Strategy

Investing in asset-centric companies and product-enabling platform technologies with proprietary products.

Vintage:2020
Fund size:over €200 million
Target:Up to 15 companies

Current Portfolio